Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-santalol is a naturally occurring sesquiterpene alcohol and a primary bioactive constituent of sandalwood oil, derived from the heartwood of *Santalum album*. It has demonstrated significant chemopreventive and anti-tumor activities in various preclinical models, particularly in skin cancer and melanoma. Its mechanism of action involves the induction of G2/M phase cell cycle arrest by modulating key regulatory proteins such as cyclin B1, cdc2, and p21, as well as the selective disruption of the actin cytoskeleton in malignant cells. Additionally, alpha-santalol has been shown to induce apoptosis and influence p53 expression, exhibiting selective toxicity toward cancer cells while sparing normal human keratinocytes at therapeutic concentrations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-santalol.